We hypothesize that pre-treatment rather than concurrent treatment with sunitinib or bevacizumab prior to standard chemotherapy in human epidermal growth factor receptor 2 (HER2)-negative breast cancer, along with a lower dose of the anti-angiogenic agent, will improve and “normalize” the tumor vasculature making it more efficient for intra-tumoral chemotherapy drug delivery. Here, ERBB2 is linked to breast carcinoma.